Company intelligence / Profile preview

Lanzhou Institute of Biological Products Co., Ltd.

Lanzhou, Gansu, Chinavacmic.com ↗
Ownership
Private
Employees
~1500
Development stage
Other
01

Overview

Lanzhou Institute of Biological Products has a long track record with dozens of approved prophylactic and combination vaccines targeting major infectious diseases endemic to China. Its portfolio includes widely used childhood combination shots such as DTP (diphtheria-tetanus-acellular pertussis) and specialized agents like live plague vaccine. It also produces plasma-derived therapeutics under its Sinopharm Lanzhou Biopharmaceuticals brand. The company played an active role during the COVID‑19 pandemic both domestically and internationally through CNBG partnerships. [2][3]

Therapeutic areas
HematologyInfectious Diseases
Modalities
Prophylactic vaccines[1]Live attenuated vaccines[1]Combination vaccines[1]Multivalent vaccines[1]Inactivated vaccines[1]Blood products (albumin, immunoglobulin)[3]
Industry
Pharma
02

Drug pipeline

11 assets

lanbotulinumtoxin-A

4

10 more assets in the full pipeline.

03

Partnerships

CNBG/Sinopharm group companiesCollaborations with Chinese government agenciesInternational assistance projects via CNBG/Sinopharm umbrella during COVID‑19 response efforts including overseas deployment to UAE etc.; academic collaborations possible due to postdoctoral station status but specific partners not listed publicly.[2]

Beyond the preview

Go deeper on Lanzhou Institute of Biological Products Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lanzhou Institute of Biological Products Co., Ltd..

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call